title: Examples of how the pharmaceutical industries distort the evidence of drug safety: the case of pioglitazone and the bladder cancer issue.
authors.affiliation: Department of Medical Pharmacology and Toxicology, University Hospital CHRU Montpellier, Montpellier, France.|Department of Pharmacoepidemiology, INSERM U1027, Faculty of Medicine, Paul Sabatier University, Toulouse, France.
authors.forename: Jean-Luc
authors.initials: JL
authors.lastname: Faillie
authors.affiliation: Department of Medical Pharmacology and Toxicology, University Hospital CHRU Montpellier, Montpellier, France.|INSERM U1058, Faculty of Medicine, Montpellier, France.
authors.forename: Dominique
authors.initials: D
authors.lastname: Hillaire-Buys
mesh_terms: D000818:Animals; D004345:Drug Industry / Q000331:legislation & jurisprudence* / Q000592:standards; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects*; D017891:Pharmacoepidemiology / Q000639:trends; D000077205:Pioglitazone; D015871:Scientific Misconduct / Q000331:legislation & jurisprudence* / Q000639:trends; D045162:Thiazolidinediones / Q000009:adverse effects*; D001749:Urinary Bladder Neoplasms / Q000139:chemically induced* / Q000453:epidemiology*
chemical_list: D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077205:Pioglitazone
keywords: drug safety; pharmaceutical industry; pharmacoepidemiology; pharmacovigilance; pioglitazone